Results 61 to 70 of about 46,899 (191)

Epidermal Growth Factor Receptor and c-erbB-2 Contents in Unresectable (UICC R1 or R2) Gastric Cancer

The International Journal of Biological Markers, 2003
Background Epidermal growth factor receptor (EGFR) and c-erbB-2 are membrane receptors expressed in a variety of solid human cancers and directly correlated with poor prognosis.
I. García, J.M. Del Casar, M.D. Corte, M.T. Allende, J.L. García-Muñiz, F. Vizoso   +5 more
doaj   +1 more source

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Breast Cancer Research, 2017
Background The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur ...
Sinead Toomey, Alexander J. Eustace, Joanna Fay, Katherine M. Sheehan, Aoife Carr, Malgorzata Milewska, Stephen F. Madden, Ausra Teiserskiene, Elaine W. Kay, Norma O’Donovan, William Gallagher, Liam Grogan, Oscar Breathnach, Janice Walshe, Catherine Kelly, Brian Moulton, M. John Kennedy, Guiseppe Gullo, Arnold D. Hill, Colm Power, Deirdre Duke, Niamh Hambly, John Crown, Bryan T. Hennessy   +23 more
doaj   +1 more source

Identification of Crucial Drug Targets and Pathways to Reprogram Drug Resistance Through Epigenetic Modulation in Advanced Lung Cancer Using Integrated Bioinformatics Approach

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Resistance to chemotherapy, which is demonstrated in almost every patient with advanced‐stage lung cancer (ALC), underscores an urgent need to unravel the underlying molecular mechanisms and identify novel strategies to overcome drug resistance. In the present study, an attempt was made to identify epigenetic targets and modulators that can be
Okibur Rahman, Mossammat Rima Akter, Nur Alam   +2 more
wiley   +1 more source

Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis

Advances in Urology, 2012
The prognostic importance of examining ErbB receptor family expression in human bladder cancer remains uncertain. Using published evidence, we examined the clinical value and the updated results of clinical trials targeting ErbB receptor family members ...
Yuh-Shyan Tsai, Hong-Lin Cheng, Tzong-Shin Tzai, Nan-Haw Chow   +3 more
doaj   +1 more source

Enhanced antiproliferative and apoptotic response to combined treatment of γ-tocotrienol with erlotinib or gefitinib in mammary tumor cells

BMC Cancer, 2010
Background Aberrant ErbB receptor signaling is associated with various types of malignancies. γ-Tocotrienol is a member of the vitamin E family of compounds that displays potent anticancer activity that is associated with suppression in ErbB receptor ...
Sylvester Paul W, Wali Vikram B, Bachawal Sunitha V   +2 more
doaj   +1 more source

Molecular Mediators Associated With Myelination, Demyelination, and Remyelination in the Peripheral Nervous System

Journal of the Peripheral Nervous System, Volume 31, Issue 3, September 2026.
ABSTRACT The peripheral nervous system (PNS) is responsible for innervating all regions of the body outside of the central nervous system (CNS), the latter consisting of the brain, spinal cord, and optic nerves. While myelin is an essential component for the efficient functioning of both CNS and peripheral nerve cells, it is particularly important for ...
Kathleen Margaret Hagen, Shalina Sheryl Ousman   +1 more
wiley   +1 more source

Activation of Neuregulin 1/ErbB Signaling Is Involved in the Development of TOCP-Induced Delayed Neuropathy

Frontiers in Molecular Neuroscience, 2018
Organophosphate-induced delayed neuropathy (OPIDN) is characterized by progressive axonal degeneration and demyelination of the spinal cord and sciatic nerves.
Hai-Yang Xu, Pan Wang, Ying-Jian Sun, Ying-Jian Sun, Ming-Yuan Xu, Li Zhu, Yi-Jun Wu   +6 more
doaj   +1 more source

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy, Andrea Glidden, Tracy Locke, Amy Scales, Elizabeth Gatewood, Jean‐Philippe Blanck, Jessica Castaneda‐Gill, Sharlin Patel, Yolanda D. Mahnke, Xuan Wang, Page Blas   +10 more
wiley   +1 more source

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers

Therapeutic Advances in Medical Oncology, 2018
Background: The application of genomic technologies to patient tumor samples identified groups of signaling pathways which acquire activating mutations.
Malgorzata Milewska, Mattia Cremona, Clare Morgan, John O’Shea, Aoife Carr, Sri HariKrishna Vellanki, Ann M. Hopkins, Sinead Toomey, Stephen F. Madden, Bryan T. Hennessy, Alex J. Eustace   +10 more
doaj   +1 more source

Interkingdom Endodontic Biofilm Supernatant Induces a Biphasic Inflammatory and Metabolic Transcriptional Response in Dental Pulp Stem Cells In Vitro

Clinical and Experimental Dental Research, Volume 12, Issue 4, August 2026.
ABSTRACT Objectives To investigate how soluble byproducts derived from a four‐species endodontic biofilm model impact the viability, transcriptomic profile, and inflammatory response of human dental pulp stem cells (DPSCs). Methods A sterile‐filtered supernatant was extracted from an established interkingdom endodontic biofilm model comprising ...
Saeed S. Alqahtani, Sumaya Abusrewil, Othman Baradwan, Om Alkhir Alshanta, Ryan Kean, William McLean, Jason L. Brown, Christopher J. Nile   +7 more
wiley   +1 more source